Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00983346 · ClinicalTrials.gov registry record · Phase 2
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
A Phase 2 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00983346 is a Phase 2 study that was terminated before completion, run by University of Utah. The registered enrollment target is 17 participants.
The verdict
NCT00983346, a Phase 2 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
OBJECTIVES * Primary: To evaluate the bone anabolic effect of bortezomib in patients with smoldering myeloma. * Secondary: To evaluate the effect of bortezomib on the natural history of smoldering myeloma.
Interventions
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-10 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00983346
The ClinicalTrials.gov registry entry for NCT00983346 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bortezomib is the first listed.
NCT00983346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00983346 about?
NCT00983346 is a clinical study titled "Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients". OBJECTIVES * Primary: To evaluate the bone anabolic effect of bortezomib in patients with smoldering myeloma. * Secondary: To evaluate the effect of bortezomib on the natural history of smoldering myeloma.
What is the current status of trial NCT00983346?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2009-10. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00983346?
The interventions under investigation include: Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00983346?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.